Autoimmune Myopathies: Where Do We Stand?

The Battle Against COVID-19: Where Do We Stand Now?

Adhesive small bowel obstruction: where do we stand now?

Adhesive small bowel obstruction (ASBO) is one of the most frequently encountered disorders in Emergency Surgery Departments worldwide without negligible hospital admission rates and social costs (1,2). Notwithstanding significant improvements in techniques and materials, intra-abdominal adhesions following abdominal surgery still represent a major unsolved and debated issue harbouring challeng...

Evidence - based CAM: Where does it stand?

In the past 10 years evidence - based medicine (EBM) has developed well in all aspects of allopathic medicine giving a new dimension to patient care including cost reduction and attention to medical ethics. With the public and medical community return to complementary and alternative medicine (CAM) in the last two decades there has been a call for evidence - based CAM … in the same way that all...

Progress in inflammatory myopathies: good but not good enough

During the past decade there have been remarkable achievements in the immunopathogenesis of the inflammatory myopathies that laid the grounds for more eVective therapeutic interventions. This editorial summarises where we stand today in our understanding of these disorders and their treatment, identifies key biological issues that need further study, and considers possibilities of applying new ...

High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.

Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specificall...